AMX0035 slowed functional decline in ALS in phase 2, but phase 3 (PHOENIX) was negative and it was withdrawn from the market in 2024.
Confidence
Debated
Level of evidence
●●●●●○ Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisAMX0035 (phenylbutyrate + taurursodiol)Amyotrophic lateral sclerosis (ALS)
What the sources say
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).